AstraZeneca’s Tagrisso Accepted for Use in Scotland to Treat EGFR Mutated Advanced Lung Cancer

AstraZeneca’s Tagrisso) has been accepted for use as a monotherapy for the first-line treatment of adult patients with locally advanced or metastatic NSCLC with activating EGFR mutations in Scotland.